PurIST®
Pancreatic Ductal Adenocarcinoma (PDAC)
CommercialActive
Key Facts
Indication
Pancreatic Ductal Adenocarcinoma (PDAC)
Phase
Commercial
Status
Active
Company
About GeneCentric Therapeutics
GeneCentric Therapeutics is a private, commercial-stage diagnostics company pioneering integrated liquid biopsy solutions for precision oncology. Its core innovation is the GenomicsNext™ platform, powered by proprietary ExpressCT™ technology, which infers gene expression from standard ctDNA sequencing data, adding a critical new dimension to liquid biopsies. The company has a commercial product, PurIST®, for pancreatic cancer subtyping, and is advancing its platform through strategic collaborations with biopharma and diagnostic partners to enhance drug development and clinical decision-making.
View full company profileTherapeutic Areas
Other Pancreatic Ductal Adenocarcinoma (PDAC) Drugs
| Drug | Company | Phase |
|---|---|---|
| M2T™ Program (unspecified) | Leukogene Therapeutics | Preclinical |
| IPB-106 | Interplay Bio | Discovery |
| IPB-107 | Interplay Bio | Discovery |
| SIWA318H | SIWA Therapeutics | Preclinical |